Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis

被引：0
|
作者：
Wolowacz, S. E.
Seal, B. S.
Tangirala, M.
机构：
[1] RTI Hlth Solut, Manchester, Lancs, England
[2] Sanofi Aventis Pharmaceut, Bridgewater, NJ USA
[3] Smith Hanley Consulting Grp LLC, Lake Mary, FL USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：622S / 623S
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer
    Khalid El Ouagari
    Jon Karnon
    Thomas Delea
    Willena Talbot
    Jane Brandman
    Breast Cancer Research and Treatment, 2007, 101 : 37 - 49
  • [42] Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer
    El Ouagari, Khalid
    Karnon, Jon
    Delea, Thomas
    Talbot, Willena
    Brandman, Jane
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) : 37 - 49
  • [43] Cost-effectiveness of Taxane/platinum and doxorubicin/platinum combination therapies in adjuvant treatment of endometrial cancer
    Srinivasan, Swetha
    Nguyen, Joehl T.
    Roberts, Megan C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 308 - 308
  • [44] Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
    Mackey, J. R.
    Pienkowski, T.
    Crown, J.
    Sadeghi, S.
    Martin, M.
    Chan, A.
    Saleh, M.
    Sehdev, S.
    Provencher, L.
    Semiglazov, V.
    Press, M. F.
    Sauter, G.
    Lindsay, M.
    Houe, V.
    Buyse, M.
    Drevot, P.
    Hitier, S.
    Bensfia, S.
    Eiermann, W.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1041 - 1047
  • [45] The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer
    Norum, Jan
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (12) : 1617 - 1625
  • [46] Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer
    John, Preethi
    Bannuru, Raveendhara R.
    Cohen, Joshua T.
    Buchsbaum, Rachel J.
    Erban, John Kalil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
    Rachel Webber-Foster
    Giorgi Kvizhinadze
    Gareth Rivalland
    Tony Blakely
    PharmacoEconomics, 2014, 32 : 707 - 724
  • [48] Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
    Webber-Foster, Rachel
    Kvizhinadze, Giorgi
    Rivalland, Gareth
    Blakely, Tony
    PHARMACOECONOMICS, 2014, 32 (07) : 707 - 724
  • [49] Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
    Mirzaei, Hamid Reza
    Rasekh, Parisa Sabet
    Nasrollahi, Fatemeh
    Rasekh, Parto Sabet
    Tirabad, Zahra Akbari
    RezaMoein, Hamid
    Pour, Taban Ghaffari
    Hajian, Parastoo
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2013, 2013
  • [50] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    CANCER, 2007, 110 (03) : 489 - 498
12345